Topic: non-small cell lung cancer
Nearly a year after its former chief Eliot Forster stepped down, Immunocore has a new full-time CEO in Medimmune’s president Bahija Jallal.
AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi.
Aro Biotherapeutics raised $13 million to build its team and advance its centyrin pipeline, which includes a candidate for non-small cell lung cancer.
The past week’s biotech news included a method for regrowing nerves by turning off genes and a potential combo to treat resistant lung cancer.
The readout suggests that, if anything, adding tremelimumab to PD-L1 drug Imfinzi results in worse outcomes in metastatic NSCLC.
South Korea’s Yuhan has licensed its lung cancer drug lazertinib to Janssen Biotech for $50 million upfront and another $1.2 billion in milestones.
The setback, Merrimack Pharmaceuticals' second flop in four months, wiped 35% off the company’s stock and left its rebooted strategy in tatters.
Ziopharm Oncology’s executive vice president of R&D, Francois Lebel, M.D., is moving to cancer drugmaker Spectrum Pharmaceuticals effective Nov. 5.
TP Therapeutics netted $80 million and a new CEO as it looks to move its lead candidate in drug-resistant tumors into phase 2 early next year.